©2024 Stanford Medicine
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Not Recruiting
Trial ID: NCT01081951
Purpose
To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4)
when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian
cancer.
Official Title
A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Stanford Investigator(s)
Jonathan S. Berek, MD, MMSc
Laurie Kraus Lacob Professor
Eligibility
Inclusion Criteria:
- Diagnosed with serous ovarian cancer
- Patients who have received no more than 3 previous platinum containing treatments and
were progression free for at least 6 months following the end of the last platinum
treatment
- At least one lesion that is suitable for accurate repeated measurements
Exclusion Criteria:
- Patients receiving any systemic anticancer chemotherapy, radiotherapy (except
palliative) within two weeks from the last dose prior to study treatment
- Hypersensitivity to pre medications required for treatment with paclitaxel/carboplatin
Intervention(s):
drug: Olaparib
drug: Paclitaxel
drug: Carboplatin
drug: Drug: carboplatin
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061